NO20042021L - Himbacinanaloger som trombinreseptorantagonister - Google Patents

Himbacinanaloger som trombinreseptorantagonister

Info

Publication number
NO20042021L
NO20042021L NO20042021A NO20042021A NO20042021L NO 20042021 L NO20042021 L NO 20042021L NO 20042021 A NO20042021 A NO 20042021A NO 20042021 A NO20042021 A NO 20042021A NO 20042021 L NO20042021 L NO 20042021L
Authority
NO
Norway
Prior art keywords
receptor antagonists
optionally substituted
thrombin receptor
compounds
alkyl
Prior art date
Application number
NO20042021A
Other languages
English (en)
Other versions
NO329349B1 (no
Inventor
Samuel Chackalamannil
Yan Xia
Martin C Clasby
Mariappan Chelliah
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20042021L publication Critical patent/NO20042021L/no
Publication of NO329349B1 publication Critical patent/NO329349B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Heterosyklisk substituerte trisykliske forbindelser med formelen (I) eller et farmasøytisk akseptabelt salt derav, der: ni og nuavhengig er 0-2, Het er en eventuelt substituert mono-, di- eller trisyklisk heteroaromatisk gruppe, B er alkyl eller eventuelt substituert alkenyl, Rer -COReller et karboksy-, sulfinyl-, sulfonyl-, sulfonamid- eller aminosyrederivat, Rer haloalkyl, alkenyl, haloalkenyl, alkynyl, eventuelt substituert sykloalkyl, sykloalkyl-alkyl, aryl, arylalkyl, heteroaryl, heterosykloalkyl eller -COOH og/eller -S0H-substituert alkyl, R, R 2 , R, R,og Rer som definert i beskrivelsen, blir tilkjennegitt i tillegg til farmasøytiske preparater som inneholder dem og en fremgangsmåte for behandling av sykdommer som er assosiert med trombose, aterosklerose, restenose, hypertensjon, angina pectoris, arytmi, hjertesvikt og kreft, ved å administrere nevnte forbindelser.
NO20042021A 2001-10-18 2004-05-14 Himbacinanalogforbindelser, farmasoytiske preparater som omfatter minst en slik forbindelse, samt anvendelse av forbindelsene til fremstilling av medikamenter for hemming av trombinreseptorer NO329349B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33035901P 2001-10-18 2001-10-18
PCT/US2002/032936 WO2003033501A1 (en) 2001-10-18 2002-10-16 Himbacine analogues as thrombin receptor antagonists

Publications (2)

Publication Number Publication Date
NO20042021L true NO20042021L (no) 2004-05-14
NO329349B1 NO329349B1 (no) 2010-10-04

Family

ID=23289411

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042021A NO329349B1 (no) 2001-10-18 2004-05-14 Himbacinanalogforbindelser, farmasoytiske preparater som omfatter minst en slik forbindelse, samt anvendelse av forbindelsene til fremstilling av medikamenter for hemming av trombinreseptorer

Country Status (23)

Country Link
US (2) US7037920B2 (no)
EP (1) EP1436298B1 (no)
JP (2) JP4307260B2 (no)
KR (1) KR100960170B1 (no)
CN (1) CN100369917C (no)
AR (1) AR036832A1 (no)
AT (1) ATE525378T1 (no)
AU (1) AU2002335031C1 (no)
BR (1) BR0213967A (no)
CA (1) CA2463628A1 (no)
CO (1) CO5570668A2 (no)
EC (1) ECSP045064A (no)
HU (1) HUP0500443A3 (no)
IL (1) IL160918A0 (no)
MX (1) MXPA04003610A (no)
MY (1) MY139335A (no)
NO (1) NO329349B1 (no)
NZ (1) NZ531869A (no)
PE (1) PE20030808A1 (no)
PL (1) PL371948A1 (no)
RU (1) RU2319704C9 (no)
WO (1) WO2003033501A1 (no)
ZA (1) ZA200402849B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
JP4558331B2 (ja) 2002-04-16 2010-10-06 シェーリング コーポレイション 三環式トロンビンレセプターアンタゴニスト
US20070243632A1 (en) * 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
ATE536889T1 (de) 2003-07-08 2011-12-15 Accumetrics Inc Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten
MY143987A (en) * 2004-05-28 2011-07-29 Schering Corp Constrained himbacine analogs as thrombin receptor antagonists
JP2008510726A (ja) * 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
EP1802609A2 (en) * 2004-10-08 2007-07-04 Schering Corporation Thrombin receptor antagonists
CN101137636A (zh) * 2005-01-14 2008-03-05 先灵公司 Himbacine类似物的外型选择性合成
AR052870A1 (es) * 2005-01-14 2007-04-11 Schering Corp Sintesis de analogos de himbacina
EP2206697B1 (en) 2005-01-14 2011-10-26 Schering Corporation Exo- and diastereo-selective syntheses of himbacine analogs
US7776889B2 (en) * 2005-03-31 2010-08-17 Schering Corporation Spirocyclic thrombin receptor antagonists
US7595169B2 (en) * 2005-04-27 2009-09-29 Accumetrics, Inc. Method for determining percent platelet aggregation
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
WO2007075809A2 (en) * 2005-12-22 2007-07-05 Schering Corporation Oxazoloisoquinoline derivatives as thrombin receptor antagonists
BRPI0620641A2 (pt) * 2005-12-22 2011-11-16 Schering Corp usos de compostos antagonistas de receptor de trombina na profilaxia de complicações de cirurgia cardiopulmonar
KR20080104352A (ko) * 2006-03-29 2008-12-02 쉐링 코포레이션 트롬빈 수용체 길항제로서 유용한 모노사이클릭 및 비사이클릭 힘바신 유도체
US8003803B2 (en) * 2006-04-13 2011-08-23 Schering Corporation Fused ring thrombin receptor antagonists
EP2032560B1 (en) 2006-06-29 2013-05-01 Merck Sharp & Dohme Corp. Substituted bicyclic and tricyclic thrombin receptor antagonists
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
CN101553484A (zh) * 2006-10-04 2009-10-07 先灵公司 以喜巴辛的被改质三环单位为基础的凝血酶受体拮抗剂
AU2007305269A1 (en) * 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
EP2120879A2 (en) * 2006-12-22 2009-11-25 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
KR20100017576A (ko) * 2007-05-03 2010-02-16 아큐메트릭스, 인크. 트롬빈 수용체 길항제에 의한 혈소판 응집 억제의 측정 방법
CN101981034B (zh) 2008-02-05 2013-08-14 赛诺菲-安万特 作为par1抑制剂的三唑并哒嗪、其制备及其制备药物的用途
CN102099340A (zh) 2008-05-19 2011-06-15 先灵公司 作为因子ixa抑制剂的杂环化合物
HRP20131049T1 (hr) 2009-06-04 2013-12-06 Merck Sharp & Dohme Corp. Aktivni metabolit antagonista trombinskog receptora
AU2010259003A1 (en) 2009-06-08 2011-11-10 Merck Sharp & Dohme Corp. A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
CN104610330A (zh) * 2015-02-25 2015-05-13 成都安斯利生物医药有限公司 一种制备(e)-3-丙烯酸乙酯频呐硼酸酯的方法
ES3048448T3 (en) 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
JP2000229961A (ja) * 1998-12-11 2000-08-22 Sagami Chem Res Center ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
TWI236476B (en) * 1997-11-25 2005-07-21 Schering Corp Thrombin receptor antagonists
DE19801636A1 (de) * 1998-01-17 1999-07-22 Bayer Ag Substituierte bicyclische Lactone
AU6690001A (en) 2000-06-15 2001-12-24 Schering Corp Thrombin receptor antagonists

Also Published As

Publication number Publication date
WO2003033501A1 (en) 2003-04-24
JP4307260B2 (ja) 2009-08-05
EP1436298B1 (en) 2011-09-21
CA2463628A1 (en) 2003-04-24
CO5570668A2 (es) 2005-10-31
NZ531869A (en) 2006-11-30
AU2002335031B2 (en) 2005-06-30
BR0213967A (pt) 2005-08-30
AR036832A1 (es) 2004-10-06
ZA200402849B (en) 2005-01-14
MXPA04003610A (es) 2004-07-27
HUP0500443A3 (en) 2009-12-28
AU2002335031C1 (en) 2006-11-16
RU2319704C2 (ru) 2008-03-20
US7037920B2 (en) 2006-05-02
CN1571789A (zh) 2005-01-26
CN100369917C (zh) 2008-02-20
JP2009029820A (ja) 2009-02-12
RU2004115114A (ru) 2005-10-27
PL371948A1 (en) 2005-07-11
IL160918A0 (en) 2004-08-31
ATE525378T1 (de) 2011-10-15
JP2005529841A (ja) 2005-10-06
KR20050036845A (ko) 2005-04-20
EP1436298A1 (en) 2004-07-14
MY139335A (en) 2009-09-30
HUP0500443A2 (hu) 2005-08-29
US20030203927A1 (en) 2003-10-30
NO329349B1 (no) 2010-10-04
KR100960170B1 (ko) 2010-05-26
RU2319704C9 (ru) 2008-08-20
ECSP045064A (es) 2004-05-28
PE20030808A1 (es) 2003-09-22
US20060106050A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
MXPA04003610A (es) Analogos de himbacina como antagonistas del receptor de trombina.
JP7169327B2 (ja) イミド系タンパク質分解モジュレーター及び関連する使用方法
RU2704129C2 (ru) Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения
CN108136044B (zh) 基于酰亚胺的蛋白水解调节剂和相关使用方法
KR102534262B1 (ko) 헤테로환형 유도체 및 이의 용도
NO20081970L (no) Sulfonamidderivat med PGD2-reseptorantagonistaktivitet
NO20072344L (no) Trombineresptorantagonister.
HU228111B1 (en) Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
KR950704304A (ko) 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives)
CZ293126B6 (cs) Léčivo k léčení schizofrenie, deprese, neuróz a psychóz
NO20020811L (no) Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
NO20052802L (no) Pyrrolopyrimidinderivativer
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
ES2242407T3 (es) N-arilamidas de acidos sulfonilamino-carboxilicos en calidad de actividades de la guanilato ciclasa.
MXPA05010210A (es) Inhibidores no nucleosidos de transcriptasa inversa para tratar las enfermedades mediadas por el virus de la inmunodeficiencia humana (vih).
EA200500096A1 (ru) Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ
BG62089B1 (bg) Инхибитори на hiv реверсивна транскриптаза
CS331091A3 (en) Synergistic combination of compounds inhibiting hiv-reverse transcriptase and a pharmaceutical based thereon
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO331174B1 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister
NO20076682L (no) Nye pyridinanaloger
EP3107911B1 (en) Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees